Accès ouvert
2026
conference-abstract
OpenAlex
T. Powles, Vadim S. Koshkin, Jonathan E. Rosenberg, Nobuaki Matsubara et autres
LBA631 Background: An estimated 60%-80% of patients (pts) with UC have HER2-expressing tumors. DV is an ADC comprising a novel anti-HER2 antibody, disitamab, and an MMAE payload. DV demonstrated promising antitumor activity and a manageable safety profile as monotherapy in Chinese pts …
gb, us, jp, au, il, ca
(code pays fourni par la source)
2026
article
OpenAlex
Deepak Kilari, K. Ballman, Edward P. Gelmann, Kevin Zarrabi et autres
TPS290 Background: Landmark randomized trials established the survival benefit of adding D to ADT in mCSPC. Building on this foundation, subsequent trials (PEACE-1 and ARASENS) demonstrated further survival improvements when androgen receptor pathway inhibitors (ARPI) were added to the ADT + D …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Eugene J. Pietzak, Karla V. Ballman, Katharine Dooley, Amanda Clark et autres
TPS909 Background: BCG-Exposed NMIBC (a high grade recurrence within 24 months of prior BCG, but not meeting “unresponsive” criteria) is a large patient population with a critical need for more effective treatment strategies that prevent the development of BCG unresponsive disease/progression. The …
us
(code pays fourni par la source)
2026
article
OpenAlex
Yu-Wei Chen, Olivia Bobek, Glenn Heller, Shuang G. Zhao et autres
TPS277 Background: Recent advances in genomic sequencing have deepened our understanding of the molecular complexity of metastatic castration-resistant prostate cancer (mCRPC), revealing multiple actionable alterations that now inform biomarker-driven treatment strategies. Accordingly, germline and somatic tumor profiling is recommended for all patients …
us
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
Bradley A. McGregor, Karla V. Ballman, Gabriela Perez Burbano, Alan W.C. Tan et autres
TPS577 Background: Pembrolizumab (pembro) for one year following resection of localized high risk clear cell renal cell carcinoma (ccRCC) in a phase 3 trial resulted in improvement in relapse-free survival and overall survival (Choueiri, NEJM 2024). However, 20% of patients still experienced …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Michal Sternschuss, Karissa Whiting, Cansu Yol, Alyssa Arbuiso et autres
801 Background: Enfortumab vedotin plus pembrolizumab (EV/P) is the standard therapy for metastatic urothelial carcinoma (UC) irrespective of Nectin4 expression. The relevance of membranous (mNectin4) and cytoplasmic (cNectin4) expression remains uncertain. Methods: We retrospectively reviewed an institutional database of patients treated with …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Viranda H. Jayalath, Jordan Eichholz, Melissa Assel, Noah Frydenlund et autres
861 Background: Recent data support a pathologic response in 60-65%, including 10-20% with a pathologic complete response (CR) for patients treated with neoadjuvant chemotherapy (NAC, 4-cycles of cisplatin-based treatment) at definitive extirpative surgery; nearly 35% of patients do not respond. We evaluated …
us
(code pays fourni par la source)
2026
article
OpenAlex
Thomas Powles, Jonathan E. Rosenberg, Shilpa Gupta, Yohann Loriot et autres
TPS883 Background: While ADC + immunotherapy has been transformative as first-line therapy for aUC, treatment options are limited for pts who progress on or after standard of care immunotherapy-based therapies. Iza-bren is a potentially first-in-class ADC composed of an EGFR x HER3 …
gb, us, fr, de, ch
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
David H. Aggen, Michal Sternschuss, Karissa Whiting, Aditi Gupta et autres
827 Background: Enfortumab vedotin and pembrolizumab (EV/P) is the standard of care for metastatic urothelial carcinoma (UC). Outcomes in UC based on HER2 IHC expression and correlation between membranous Nectin-4 and HER2 IHC expression have not been reported. Methods: A retrospective cohort …
us
(code pays fourni par la source)